MyoKardia Accelerates Timing for Mavacamten Topline Phase 3 Data

Date : 07/18/2019 @ 1:29PM
Source : Dow Jones News
Stock : Sanofi (SNY)
Quote : 49.79  0.28 (0.57%) @ 1:00AM
After Hours
Last Trade
Last $ 49.79 ◊ 0.00 (0.00%)

MyoKardia Accelerates Timing for Mavacamten Topline Phase 3 Data

Historical Stock Chart

6 Months : From Jun 2019 to Dec 2019

Click Here for more MyoKardia Charts.

By Michael Dabaie


MyoKardia Inc. (MYOK) now anticipates reporting topline data from the EXPLORER-HCM trial in the second quarter of 2020, ahead of previous guidance of the second half of 2020.

Patient screening has closed for the Phase 3 EXPLORER-HCM study to assess mavacamten in treating patients with obstructive hypertrophic cardiomyopathy. Enrollment into the pivotal trial is expected to be completed by mid-August, MyoKardia said.

MyoKardia also said it re-acquired U.S. royalty rights to mavacamten and MYK-224 from Sanofi S.A. (SNY, SAN.FR). As consideration for the buyback of the U.S. royalty rights to these programs, MyoKardia is paying Sanofi $50 million upfront, with an additional $30 million payable by June 30, 2020.

MyoKardia shares were up 0.4% premarket to $50.00.


Write to Michael Dabaie at


(END) Dow Jones Newswires

July 18, 2019 09:14 ET (13:14 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest SNY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.